Michael Osborn

Cancer statistics, 2024

Cancer treatment and survivorship statistics, 2022

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

Development of a Common Outcome Data Set for Fall Injury Prevention Trials: The Prevention of Falls Network Europe Consensus

Increasing response rates to postal questionnaires: systematic review

Web-Based Versus Traditional Paper Questionnaires: A Mixed-Mode Survey With a Nordic Perspective

A guide for the design and conduct of self-administered surveys of clinicians

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Methods to increase response to postal and electronic questionnaires

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

Cancer treatment and survivorship statistics, 2019

Cancer in Adolescents and Young Adults

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Effectiveness of telephone prompts when surveying general practitioners: a randomised trial.

Youth Cancer Services in Australia: Development and Implementation. International Perspectives on AYAO, Part 3

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial